These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 29154019)

  • 21. Lack of Patient Compliance in Real-World Practice Negatively Affects Sustained Viral Response Rates to Direct Acting Agent Therapy for Hepatitis C.
    Marshall MC; Herrera JL
    Dig Dis Sci; 2018 Dec; 63(12):3228-3232. PubMed ID: 30128645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of direct-acting antiviral therapy for hepatitis C in difficult-to-treat patients in a safety-net health system: a retrospective cohort study.
    Yek C; de la Flor C; Marshall J; Zoellner C; Thompson G; Quirk L; Mayorga C; Turner BJ; Singal AG; Jain MK
    BMC Med; 2017 Nov; 15(1):204. PubMed ID: 29151365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
    Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V;
    Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of specialty care versus standard retail pharmacies for treatment of hepatitis C.
    Cohen SM; Kwasny MJ; Ahn J
    Ann Pharmacother; 2009 Feb; 43(2):202-9. PubMed ID: 19193591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients.
    Cucchetti A; D'Amico G; Trevisani F; Morelli MC; Vitale A; Pinna AD; Cescon M;
    Dig Liver Dis; 2018 Feb; 50(2):156-162. PubMed ID: 29102521
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interferon-based hepatitis C therapy in a safety net hospital: access, efficacy, and safety.
    Nordstrom EM; Keniston A; Baouchi F; Martinez-Camacho A
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):10-16. PubMed ID: 27755117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: a real-world study of 17 487 patients.
    Su F; Beste LA; Green PK; Berry K; Ioannou GN
    Eur J Gastroenterol Hepatol; 2017 Jun; 29(6):686-693. PubMed ID: 28195877
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis C virus direct-acting antiviral nonadherence: Relationship to sustained virologic response and identification of at-risk patients.
    Slevin AR; Hart MJ; Van Horn C; Rahman S; Samji NS; Szabo A; Rein L; Werner S; Saeian K
    J Am Pharm Assoc (2003); 2019; 59(1):51-56. PubMed ID: 30545782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Closing the Gap: The Challenges of Treating Hepatitis C Virus Genotype 3 Infection.
    Martin MT; Deming P
    Pharmacotherapy; 2017 Jun; 37(6):735-747. PubMed ID: 28374965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Impact of the Pharmaceutical Care Management Model of Hepatitis C Medications on the Cost at Health Insurance Level.
    Almahdi FB; Hashim AH; Albaba EAM; Salih ON; Alkasam RJ; Mosli MH; Alsulaimani AF
    Value Health Reg Issues; 2020 May; 21():230-237. PubMed ID: 32334165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population.
    Sikavi C; Chen PH; Lee AD; Saab EG; Choi G; Saab S
    Hepatology; 2018 Mar; 67(3):847-857. PubMed ID: 29108121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of functional benefit of hepatitis C therapy in a 'real-life' cohort.
    Steinebrunner N; Stein K; Sandig C; Bruckner T; Stremmel W; Pathil A
    World J Gastroenterol; 2018 Feb; 24(7):852-861. PubMed ID: 29467555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of hepatitis C with peginterferon and ribavirin in Iceland from 2002-2012].
    Fridriksson B; Bergmann OM; Olafsson S
    Laeknabladid; 2017 Mars; 103(3):125-128. PubMed ID: 28262630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis C donor positive to recipient negative solid organ transplants: Early direct acting antiviral insurance approval rates with and without documented viremia.
    Duong AT; Snyder HS; Billmeyer AL; Cox AC; Cheng NL; Ford RM; Fuller KG
    Am J Surg; 2023 Aug; 226(2):239-244. PubMed ID: 37137788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents.
    Lin M; Kramer J; White D; Cao Y; Tavakoli-Tabasi S; Madu S; Smith D; Asch SM; El-Serag HB; Kanwal F
    Aliment Pharmacol Ther; 2017 Nov; 46(10):992-1000. PubMed ID: 28949020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents.
    Tsui JI; Williams EC; Green PK; Berry K; Su F; Ioannou GN
    Drug Alcohol Depend; 2016 Dec; 169():101-109. PubMed ID: 27810652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct-acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease.
    Backus LI; Belperio PS; Shahoumian TA; Mole LA
    Hepatology; 2018 Sep; 68(3):827-838. PubMed ID: 29377196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance.
    Lo Re V; Gowda C; Urick PN; Halladay JT; Binkley A; Carbonari DM; Battista K; Peleckis C; Gilmore J; Roy JA; Doshi JA; Reese PP; Reddy KR; Kostman JR
    Clin Gastroenterol Hepatol; 2016 Jul; 14(7):1035-43. PubMed ID: 27062903
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological response.
    Welsch C; Efinger M; von Wagner M; Herrmann E; Zeuzem S; Welzel TM; Lange CM
    PLoS One; 2017; 12(2):e0171755. PubMed ID: 28196130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of Direct-acting Antivirals to Improve Clinical Condition, Fibrosis, and Liver Function in Liver Transplant Recipients Infected by Hepatitis C.
    Garcia-Pajares F; Tejedor-Tejada J; Torres-Yuste R; Almohalla-Alvárez C; Sánchez-Ocaña R; Peñas-Herrero I; Cimavilla-Román M; de Benito-Sanz M; Sánchez-Martín F; Sánchez-Antolín G
    Transplant Proc; 2019; 51(1):74-76. PubMed ID: 30655151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.